beta

ALEC

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-25-2019 03-25-2019 03-25-2019 03-25-2019 03-25-2019 03-25-2019 03-25-2019 03-25-2019 03-25-2019
Actual EPS -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48 -1.48
Consensus EPS -0.29 -0.29 -0.29 -0.29 -0.29 -0.29 -0.29 -0.29 -0.29
Estimated EPS -0.29 -0.29 -0.29 -0.29 -0.29 -0.29 -0.29 -0.29 -0.29
Number of Estimates 2 2 2 2 2 2 2 2 2
EPS Surprise -$1.19 -$1.19 -$1.19 -$1.19 -$1.19 -$1.19 -$1.19 -$1.19 -$1.19

Stats

Summary

Market Cap:

Primary Exchange:

Website: /stocks/alec

Shares Outstanding:

Float:

Dividend: (%)

Beta:

Sector:

Industry:

Short Interest ():

Ethical Flags

Longest drawdown: 41 trading days

From: 2019-04-12 To: 2019-06-12

Lowest Point:

Prevail Therapeutics Proposes IPO Terms

via: SeekingAlpha at 2019-06-13 07:46:25:000

Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...

Alector: Targeted Therapies For Neurodegenerative Diseases

via: SeekingAlpha at 2019-05-20 08:38:53:000

Shares of Alector Inc ( ALEC ) have risen by just 6% from its February 2019 IPO price point of $19. At the time the company took in around $176 million in proceeds (not including underwriter option of 1,387,500 shares). Investment banks involved included Morgan Stanley, BofA Merill Lynch, … read more...

Alector: Targeted Therapies For Neurodegenerative Diseases

via: SeekingAlpha at 2019-05-20 08:38:53:000

Shares of Alector Inc ( ALEC ) have risen by just 6% from its February 2019 IPO price point of $19. At the time the company took in around $176 million in proceeds (not including underwriter option of 1,387,500 shares). Investment banks involved included Morgan Stanley, BofA Merill Lynch, … read more...

Alector: Targeted Therapies For Neurodegenerative Diseases

via: SeekingAlpha at 2019-05-20 08:38:53:000

Shares of Alector Inc ( ALEC ) have risen by just 6% from its February 2019 IPO price point of $19. At the time the company took in around $176 million in proceeds (not including underwriter option of 1,387,500 shares). Investment banks involved included Morgan Stanley, BofA Merill Lynch, … read more...

Alector misses by $0.15, misses on revenue

via: SeekingAlpha at 2019-05-13 12:21:34:000

Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.42 misses by $0.15 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alector misses by $0.15, misses on revenue

via: SeekingAlpha at 2019-05-13 12:21:34:000

Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.42 misses by $0.15 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alector misses by $0.15, misses on revenue

via: SeekingAlpha at 2019-05-13 12:21:34:000

Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.42 misses by $0.15 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Cortexyme IPO Isn't Cheap

via: SeekingAlpha at 2019-05-06 13:59:37:000

Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh… read more...

Cortexyme IPO Isn't Cheap

via: SeekingAlpha at 2019-05-06 13:59:37:000

Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh… read more...

Cortexyme IPO Isn't Cheap

via: SeekingAlpha at 2019-05-06 13:59:37:000

Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh… read more...

Dosing underway in early-stage study of Alector's AL001 in severe dementia

via: SeekingAlpha at 2019-04-17 12:35:22:000

Alector (NASDAQ: ALEC ) announces that the first patient with frontotemporal dementia (FTD)has been dosed in the Phase 1b portion of its INFRONT study assessing the safety of multiple doses of AL001, a monoclonal antibody designed to modulate a protein expressed by nerve cells call… read more...

Dosing underway in early-stage study of Alector's AL001 in severe dementia

via: SeekingAlpha at 2019-04-17 12:35:22:000

Alector (NASDAQ: ALEC ) announces that the first patient with frontotemporal dementia (FTD)has been dosed in the Phase 1b portion of its INFRONT study assessing the safety of multiple doses of AL001, a monoclonal antibody designed to modulate a protein expressed by nerve cells call… read more...

Dosing underway in early-stage study of Alector's AL001 in severe dementia

via: SeekingAlpha at 2019-04-17 12:35:22:000

Alector (NASDAQ: ALEC ) announces that the first patient with frontotemporal dementia (FTD)has been dosed in the Phase 1b portion of its INFRONT study assessing the safety of multiple doses of AL001, a monoclonal antibody designed to modulate a protein expressed by nerve cells call… read more...

Alector reports Q4 results

via: SeekingAlpha at 2019-03-26 12:18:29:000

Alector (NASDAQ: ALEC ): Q4 GAAP EPS of -$1.48. More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alector reports Q4 results

via: SeekingAlpha at 2019-03-26 12:18:29:000

Alector (NASDAQ: ALEC ): Q4 GAAP EPS of -$1.48. More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alector reports Q4 results

via: SeekingAlpha at 2019-03-26 12:18:29:000

Alector (NASDAQ: ALEC ): Q4 GAAP EPS of -$1.48. More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Big Pharma, Green Trucks And Jobs Report (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-03-03 02:30:34:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Big Pharma, Green Trucks And Jobs Report (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-03-03 02:30:34:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Big Pharma, Green Trucks And Jobs Report (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-03-03 02:30:34:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Big Pharma, Green Trucks And Jobs Report

via: SeekingAlpha at 2019-03-02 04:01:09:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Time to look ahead after the market came off its best two-month run in years. The e… read more...

Alector: Addressing Neuroinflammation In Neurodegenerative Diseases With Potential For A Cure

via: SeekingAlpha at 2019-03-01 10:47:01:000

Alector ( ALEC ) was founded in 2013 and is based in South San Francisco, Calif. Data by YCharts (Alector, common stock price chart) IPO price= $19/share. 52-week price range= $15.55 - $22.50 Market cap= $1.35 billion Net amount raised from IPO: $163.4M. Cash reserves aft… read more...

U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs

via: SeekingAlpha at 2019-02-09 11:13:47:000

In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...

U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs

via: SeekingAlpha at 2019-02-09 11:13:47:000

In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...

U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs

via: SeekingAlpha at 2019-02-09 11:13:47:000

In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...

U.S. IPO Weekly Recap: 2 Billion-Dollar Biotechs Cap A Mixed Week For Biotech IPOs

via: SeekingAlpha at 2019-02-09 11:13:47:000

In the second week after the SEC opened, we saw a number of launches and two billion-dollar biotechs, Alector (ALEC) and Gossamer Bio (GOSS), price their IPOs. Another biotech, Harpoon Therapeutics (HARP), along with three SPACs, also priced their IPOs. Alector, a Phase 1 biotech developing … read more...

Alector prices IPO at $19

via: SeekingAlpha at 2019-02-07 02:40:03:000

Alector (NASDAQ: ALEC ) prices its IPO of 9.25M shares of common stock at $19.00/share, for expected gross proceeds of $176M. More news on: Alector, Inc., Healthcare stocks news, Read more … read more...

Alector prices IPO at $19

via: SeekingAlpha at 2019-02-07 02:40:03:000

Alector (NASDAQ: ALEC ) prices its IPO of 9.25M shares of common stock at $19.00/share, for expected gross proceeds of $176M. More news on: Alector, Inc., Healthcare stocks news, Read more … read more...

Alector Announces Pricing of Initial Public Offering

via: Business Wire at 2019-02-06 19:59:00:000

Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per sh… read more...

Alector Announces Pricing of Initial Public Offering

via: Business Wire at 2019-02-06 19:59:00:000

Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per sh… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX